Sadiya Khan At the policy level, Khan et al highlighted issues around high out-of-pocket costs, restrictions placed on the ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

A new Northbrook pharma will work to bring its obesity treatment to market that it says holds advantages over Ozempic and its ...

The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

[5] Dulaglutide: A type of glucagon-like peptide-1 (GLP-1) receptor agonist approved by the U.S. Food and Drug Administration ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Hims & Hers anticipates selling a generic version of NVO's liraglutide ... Novo shareholders should be aware that GLP-1 agonists have become an increasingly large proportion of company revenues.

GLP-1 receptor agonists, originally developed for managing type 2 diabetes ... Perceived high costs, inconsistent insurance ...